Volume 11, Issue 3, September 2012

ISSN: 2195-9595 (Online)

In this issue (9 articles)

  1. No Access

    Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors)

    Hepatitis C Therapy: Lessons of the Last Two Decades

    Sudeep Tanwar, Paul M. Trembling, Geoffrey M. Dusheiko Pages 119-127
  2. No Access

    Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors)

    IL28B: Current and Future Use

    S. G. Chen Yi Mei, P. V. Desmond, A. J. Thompson Pages 136-145
  3. No Access

    Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors)

    Non-interferon Therapies for Hepatitis C

    Fernando E. Membreno, Eric J. Lawitz Pages 146-152
  4. No Access

    Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors)

    Cyclophilin Inhibitors

    Robert Flisiak, Anna Parfieniuk-Kowerda Pages 153-159
  5. No Access

    Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors)

    Telaprevir and Boceprevir: The Future Is Now

    Beatriz Calle Serrano, Michael P. Manns Pages 160-171
  6. No Access

    Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors)

    Second Generation Protease Inhibitors and Nucleotide Inhibitors

    Syed-Mohammad Jafri, Stuart C. Gordon Pages 172-180
  7. No Access

    Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors)

    NS5A Inhibitors

    Christopher O’Brien, Nicholas Agresti Pages 181-187
  8. No Access

    Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors)

    Resistance to Direct-Acting Antivirals

    Jean-Michel Pawlotsky Pages 188-194